Why the study?
Do pharmacological interventions targeting endothelial dysfunction prevent or improve age-related macular degeneration in at-risk patients or those with the disease?
Do pharmacological interventions targeting endothelial dysfunction prevent or improve age-related macular degeneration in at-risk patients or those with the disease?
Answers are grounded in this paper and cite their sources.
Pharmacological treatments targeting systemic endothelial dysfunction, such as statins and RAAS inhibitors, represent a potential therapeutic strategy for preventing and managing age-related macular degeneration.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Tamás Fischer (2015) conducted a review in Age-related macular degeneration. Pharmacological therapies targeting endothelial dysfunction was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: